In this webinar, a sensitive, robust and cost-effective method will be presented for the bioanalysis of IFX with LC–MS/MS by means of a target-based pre-analytical sample purification.
The therapeutic monoclonal antibody, Infliximab (IFX), is a widely used drug for the treatment of several inflammatory autoimmune diseases. However, approximately 10% of patients develop anti-infliximab antibodies (ATIs) rendering the treatment ineffective. Early detection of underexposure to unbound IFX would result in a timely switch of therapy, which could aid in the treatment of this disease.
Mohsin El Amrani, Department of Clinical Pharmacy, Division of Laboratory Medicine and Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
Mohsin El Amrani obtained a Bachelor degree at the Institute of Life Sciences and Chemistry (Hogeschool van Utrecht) majoring in Analytical Chemistry. In 2014 he obtained a Master’s degree in Analytical Sciences at Vu University in Amsterdam. Currently he is working at UMCU where he holds a position as a research analyst and PhD candidate in proteomics.
Disclaimer: For Research Use Only. Not for use in diagnostic procedures.
* Required field
© 2017 Thermo Fisher Scientific Inc. Todos los derechos reservados.
Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.